Understanding NMOSD
NMOSD is a debilitating autoimmune disease of the central nervous system. Find out more about the condition here.
Downloads: Download
Finding hope with a rare disease
Planning for a future beyond neuromyelitis optica spectrum disorder (NMOSD)
Through medical innovation and partnerships, Roche is providing new options to people living with NMOSD, a rare autoimmune disorder, to help them retain as much independence as possible.
NMOSD is a rare, lifelong and debilitating autoimmune disease of the central nervous system, primarily damaging the optic nerve(s) and spinal cord. It affects around 200,000 people worldwide and is most common among women, affecting people in the prime of their lives, usually in their 30s and 40s.
People with NMOSD experience unpredictable, severe relapses directly causing cumulative, irreversible, neurological damage and disability. One relapse may lead to permanent blindness, muscle weakness, paralysis and, in some cases, death. Before targeted diagnostic and treatment of NMOSD, within five years 50% of individuals with NMOSD required a wheelchair and 62% of people with NMOSD were functionally blind.
As a result, preventing relapses is the primary goal for NMOSD management.
Living with NMOSD
Finding hope in difficult times
Michelle’s diagnosis with NMOSD initially devastated her, but she refuses to let it prevent her from living her life. She shares her story here.
moreDon't give up living because you've been given a rare, serious diagnosis. Make the most of what time you have here and keep living. There's a lot of help to be had. Keep moving forward."
